Jump to content

Icotrokinra

Add links
From Wikipedia, the free encyclopedia
Icotrokinra
Identifiers
3D model (JSmol)
UNII
  • InChI=1S/C90H120N20O22S2/c1-48-16-14-20-59-57(46-97-72(48)59)42-64-79(122)99-60(21-12-13-34-96-50(3)112)77(120)108-75(89(7,8)134-133-88(5,6)74(98-51(4)113)84(127)104-66(44-69(93)115)81(124)107-73(49(2)111)83(126)102-64)85(128)103-62(39-52-23-26-58(27-24-52)132-37-32-91)78(121)100-63(40-53-22-25-55-18-10-11-19-56(55)38-53)82(125)109-90(30-35-131-36-31-90)87(130)106-61(28-29-71(117)118)76(119)101-65(43-68(92)114)80(123)105-67(41-54-17-15-33-95-45-54)86(129)110(9)47-70(94)116/h10-11,14-20,22-27,33,38,45-46,49,60-67,73-75,97,111H,12-13,21,28-32,34-37,39-44,47,91H2,1-9H3,(H2,92,114)(H2,93,115)(H2,94,116)(H,96,112)(H,98,113)(H,99,122)(H,100,121)(H,101,119)(H,102,126)(H,103,128)(H,104,127)(H,105,123)(H,106,130)(H,107,124)(H,108,120)(H,109,125)(H,117,118)/t49-,60+,61+,62+,63+,64+,65+,66+,67+,73+,74-,75-/m1/s1
    Key: IVFNYXYPMJQSGF-QMRCQSNESA-N
  • hydrochloride: Key: CRRBEZHEBBHPMQ-OFJNNPTNSA-N
  • CC1=C2C(=CC=C1)C(=CN2)C[C@H]3C(=O)N[C@H](C(=O)N[C@@H](C(SSC([C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3)[C@@H](C)O)CC(=O)N)NC(=O)C)(C)C)(C)C)C(=O)N[C@@H](CC4=CC=C(C=C4)OCCN)C(=O)N[C@@H](CC5=CC6=CC=CC=C6C=C5)C(=O)NC7(CCOCC7)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC8=CN=CC=C8)C(=O)N(C)CC(=O)N)CCCCNC(=O)C
Properties
C90H120N20O22S2
Molar mass 1898.19 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Icotrokinra is an investigational targeted oral peptide used in the treatment of plaque psoriasis.[1]

Description

[edit]

Icotrokinra is designed to selectively block the IL-23 receptor, which plays a vital role in the pathogenic T-cell activation of plaque psoriasis.[2][3]

The phase 3 ICONIC-LEAD trial has been evaluating icotrokinra in adult and adolescent patients aged 12 years and older with moderate-to-severe cases of plaque psoriasis.[2][4]

The Phase 3 ICONIC-TOTAL study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo.[2][5]

Phase 3 studies ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 will evaluate the safety and efficacy of icotrokinra compared with both placebo and deucravacitinib in moderate-to-severe plaque psoriasis.[6][7]

Icotrokinra was jointly discovered by Johnson & Johnson (J&J) and Protagonist Therapeutics.[2]

References

[edit]
  1. ^ "J&J pill clears skin in two late-stage psoriasis studies". BioPharma Dive. Archived from the original on 2024-11-19. Retrieved 2024-11-25.
  2. ^ a b c d "Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results". JNJ.com. 2024-11-18. Archived from the original on 2024-11-23. Retrieved 2024-11-25.
  3. ^ "Positive Phase 3 Results Announced for JNJ-2113 Treatment of Psoriasis". HCP Live. 2024-11-19. Retrieved 2024-11-25.
  4. ^ "A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (ICONIC-LEAD)". clinicaltrials.gov. Archived from the original on 2024-11-19. Retrieved 2024-11-25.
  5. ^ "A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (ICONIC-TOTAL)". clinicaltrials.gov. Archived from the original on 2024-11-19. Retrieved 2024-11-25.
  6. ^ "A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis". clinicaltrials.gov. Archived from the original on 2024-07-19. Retrieved 2024-11-25.
  7. ^ "A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)". clinicaltrials.gov. Archived from the original on 2024-11-18. Retrieved 2024-11-25.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Icotrokinra&oldid=1260208393"